Cambrian Bio
3 known investors
Cambrian Bio is a clinical-stage biopharmaceutical company developing precision therapeutics targeting metabolic pathways associated with aging, including AMPK and mTOR. Its lead asset, ATX-304, is the first AMPK Network Activator in clinical development for obesity and prediabetes.